The shares of Senores Prescription drugs Restricted had been buying and selling at ₹570.70 up by ₹36.90 or 6.91 per cent on the NSE right now at 2.32 pm.
Senores Prescription drugs Restricted introduced the acquisition of US advertising and marketing rights for Roflumilast tablets by means of its American subsidiary. The take care of Breckenridge Pharmaceutical, Inc., a subsidiary of Towa Worldwide, consists of the USFDA-approved Abbreviated New Drug Utility (ANDA) for 250 mcg and 500 mcg tablets.
Roflumilast is used to cut back COPD exacerbations in sufferers with extreme persistent bronchitis. The US marketplace for the drug was valued at roughly $32 million as of June 2024, in keeping with IQVIA knowledge, and $46 million as of September 2024, per Symphony.
- Additionally learn: MRO-TEK Realty rebrands as Umiya Buildcon Restricted
The Ahmedabad-based firm plans to fabricate the drug at its US facility and can fund the acquisition utilizing proceeds from its latest IPO. Managing Director Swapnil Shah stated the acquisition aligns with the corporate’s technique to enter area of interest, under-penetrated generic formulations.
Senores presently has 24 ANDAs and 21 CMO/CDMO business merchandise authorised for US distribution. The corporate operates two formulation manufacturing amenities – an FDA-approved plant in Atlanta, USA, and a WHO-GMP authorised facility in Chhatral, India. It additionally maintains two API manufacturing amenities close to Ahmedabad and three R&D websites throughout India and the USA.
